VK-1850 (VK1850) is a small-molecule inhibitor of the DNA binding activity of EBNA1 (Epstein-Barr nuclear antigen1).

VK4-116 is a novel potent, highly selective dopamine D3 receptor (D3R) antagonist with Ki of 6.8 nM, displays >1,000-fold selectivity over D2R.

VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.

VNRX-5133 is a highly potent and specific beta-lactamase inhibitor, for use in combination with a licensed beta-lactam antibiotic.

VO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.

Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.

VP-14637 (MDT-637) is a novel RSV fusion inhibitor with EC50 of 1.4 nM, reduces RSV replication by inhibition of the F-protein function.

VPC-80051 (VPC80051) is the first small molecule inhibitor of hnRNP A1 splicing activity, targets RNA-binding domain (RBD) of hnRNP A1.

VPS34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.

VS-II-173 is a highly potent Pim1 and Pim3 inhibitor with IC50 of 70 and 20 nM respectively, and a potent and selective inducer of AML cell death (IC50=5.5 uM, Molm-13 cell).

VTI-1002 is a potent and specific inhibitor of human (K i = 4.4 ± 2.0 nM) and murine (IC 50 = 179 ± 18 nM) GzmB, with minimal activity (IC 50 > 300 nM) against Cathepsin-G, neutrophil elastase and caspases (−3, −4, −5, −7, −8 and −9). In addition to its high specificity for GzmB, VTI-1002 is retained in murine skin for up to 24 hours and exhibits minimal toxicity in vivo with no observed adverse effects after 30 consecutive days of systemic administration in mice [31]. VTI-1002-mediated GzmB inhibition was first reported to augment type I collagen fibrillogenesis and improve tensile strength in a murine diabetic burn model, notably by preventing decorin cleavage and dermal fibrillar collagen network disorganization.

VTP-43742 (VTP43742) is a highly potent, selective, oral RORγt inverse agonist for the treatment of autoimmune disorders, including multiple sclerosis and psoriasis..

VTX-27 is a selective protein kinase C θ (PKC θ) inhibitor, with Kis of 0.08 nM and 16 nM for PKC θ and PKC δ.

VU 0238429 is positive allosteric modulator of muscarinic acetylcholine receptor subtype 5 (mAChR5 or M5), with an EC50 of 1.16 μM.

VU 0240551 is a potent, selecticve inhibitor of the neuronal K-Cl cotransporter KCC2 with IC50 of 568 nM in K+ uptake assay in KCC2-overexpressing cells.

VU 0365114 is a mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM.

VU 0650786 (VU0650786, VU-0650786) is a potent and selective, CNS penetrant mGlu3 negative allosteric modulator with IC50 of 392 nM, with no significant activity against other mGlus (IC50>10 uM).

VU 10010 is a selective, allosteric potentiator of M4 mAChR (EC50=33 and 0.7 nM for ACh in the absence and presence of VU10010 respectively), has no activity at other mAChR subtypes.

VU 6008667 is a potent, highly selective M5 negative allosteric modulator with IC50 of 1.2 uM.

VU0134992 (VU 0134992) is a potent, selective blocker of the inward rectifier potassium channel Kir4.1 (KCNJ10) with IC50 of 0.97 uM in whole-cell patch clamp electrophysiology assays; displays 9-fold selectivity for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 uM) at -120 mV; VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2, is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1, and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2 in Tl+ flux assays; causes dose-dependent diuresis, natriuresis, and kaliuresis in rats after oral treatment; VU0134992 represents the first in vivo-active tool compound for probing the therapeutic potential of Kir4.1 as a novel diuretic target for the treatment of hypertension.

VU0152099 is a potent, selective, CNS-penetrant positive allosteric modulator of M4 mAChR with EC50 of 403 nM.

VU0155069 is a potent, selective phospholipase D1 (PLD1) inhibitor with IC50 of 46 nM, 20-fold selectivity over PLD2 (IC50=933 nM).

VU0155094 is a potent, selective pan-Group III mGlu positive allosteric modulator with IC50 of 3.43/1.5/0.93 uM for mGlu8/7/4, respectively.

VU0400195 (ML 182) is a potent, selective, brain penetrant and orally active positive allosteric modulator of mGluR4 with EC50 of 291 nM and 376 nM for human and rat mGluR4, respectively.

VU0410425 is a potent, selective negative allosteric modulator of rat mGluR1 with IC50 of 140 nM, inactive at human mGluR1 (IC50>30 uM)..

VU0418506 (VU 0418506) is a potent and selective mGlu4 positive allosteric modulator (PAM) with EC50 of 68 nM (hmGlu4).

VU0422288 is a potent, selective, CNS-penetrant pan-Group III mGlu positive allosteric modulator with IC50 of 110/146/130 nM for mGlu8/7/4, respectively, displays >30-fold selectivity over groups I and II mGlus (mGlu1/2/3/5/6)..

VU0453595 (VU453595) is a potent, selective M1 positive allosteric modulator (PAM) with EC50 of 3.2 uM (rM1).

VU0463271 is a potent KCC2 antagonist, with an IC50 of 61 nM.

VU0466551 (VU-0466551) is a potent, selective, small-molecule GIRK activator with EC50 of 70.6 nM (GIRK1/2 channels).

VU0467154 (VU 0467154) is a potent, selective M4 mAChR positive allosteric modulator with EC50 of 17.7 nM.

VU0467485 (VU-0467485, AZ13713945) is potent, selective, and orally bioavailable muscarinic acetylcholine receptor 4 (M4) positive allosteric modulator with EC50 of 78.8 nM (hM4).

VU0481443 (ML380) is a potent, selective and CNS penetrant M5 positive allosteric modulator (PAM) with EC50 of 190 nM for hM5.

VU0486846 is a novel potent, highly selective M1 mAChR positive allosteric modulation (PAM) with EC50 of 0.31 uM.

VU0652957 (VU2957, Valiglurax) is a potent, selective mGlu4 positive allosteric modulator (PAM) with EC50 of 64.6 nM in calcium mobilization human mGlu4/Gqi5 assays; showes excellent pharmacokinetics across species (low CLps, %F > 35%), an acceptable CYP profile (>30 uM vs. 3A4, 2D6 and 2C9, 12.5 uM vs. 2C19 and 1.5 uM vs. 1A2), no CYP induction or timedependent inhibition and excellent metabolite coverage across species; also shows attractive predicted human PK parameters (CLps 5-9 mL/min/kg, Vds 1-2 L/kg and t1/2 2-4 hours).

VU0810464 (VU 0810464, VU464) is a selective neuronal GIRK channels activator, displays nanomolar potency for GIRK1/2 (EC50=163 nM) and improved brain penetration.

VU-29 (DPAP) is a potent, selective and allosteric potentiator of rat mGlu5 receptor with EC50 of 9 nM, displays >50-fold selectivity over mGlu1 and mGlu2 receptor (EC50=557 nM and 1.51 uM).

VU6001221 is a potent choline transporter (CHT) inhibitor with IC50 of 270 nM.

VU6001376 (VU 6001376, VU-6001376) is a potent, selective, positive allosteric modulator of mGlu4 with EC50 of 28 nM, 49% Glu Max, shows no activity against other 7 mGlu receptors.

VU6004256 (VU 6004256) is a highly potent, selective M1 muscarinic acetylcholine receptor (mAChR) positive allosteric modulator with EC50 of 155 nM (mouse M1), significant selectivity over M2-M5 (EC50>30 uM).

VU6007477 is a novel potent, selective, CNS penetrant M1 positive allosteric modulator (PAM) with EC50 of 230 nM, 93% ACh max with minimal M1 agonist activity.

VU6007678 is a potent, subtype selective, CNS penetrant M5 mAChR positive allosteric modulator (PAM) with EC50 of 41 nM.

VU6009003 is a potent, selective, CNS penetrant mAChR M4 positive allosteric modulator with EC50 of 197 nM and 437 nM for human and rat M4, respectively..

VU661013 is a potent and selective MCL-1 inhibitor.

VUF-10214 is a potent, selective histamine H4 receptor (H4R) ligand with pKi of 7.4, shows anti-inflammatory properties in vitro..

VUF15000 (VUF-15000) is the first photoswitchable GPCR Histamine H3 receptor agonist (pKi=8.42), displays >300-fold selective for hH3R over hH1R and hH2R.

VUT-MK142 is a cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes, shows superior cardiomyogenic activity over cardiogenol C.

VU-WS113 is a potent inhibitor of Wnt signaling with EC50 of 80 nM that selectively potentiates CK1α kinase activity..

VX-148 is a potent, uncompetitive, orally bioavailable IMPDH inhibitor with Ki of 6 nM against IMPDH type II enzyme.

VX-702 is a highly selective inhibitor of p38 MAPKα with IC50 of 4-20 nM.

VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively.

VX-984 (M 9831) is a potent, selective inhibitor of DNA-PK with IC50 of 88±64 nM for inhibition of DNA-PKcs autophosphorylation (Ser2056) in A549 lung cancer cells, with good selectivity versus other PI3K family members..

VX-984 is a potent DNA-PKinhibitor.

W146 is a potent, selective S1P1 antagonist with Ki of 18 nM, displays no effect at S1P2, S1P3 or S1P5, enhances capillary leakage and restores lymphocyte egress in vivo. .

W-212393 (MT-7716 free base) is a highly potent, brain penetrant ORL1 receptor (NOP receptor) agonist with Ki of 0.76 and 0.50  nM for rat and human ORL1 receptors, respectively.

WAY-100635 is a potent, silent antagonist of 5-HT1A receptors (IC50 = 2.2 nM; Ki = 0.84 nM for rat 5-HT1A receptors). Displays 100-fold selectivity for 5-HT1A over other 5-HT subtypes. Also exhibits agonist activity at dopamine D4 receptors.

WAY-196025 is a potent, selective, and orally active inhibitor of cPLA2α with IC50 of 12 nM for LTB4 inhibition.

WAY-267464 (WAY267464) is a potent, selective, non-peptide oxytocin receptor agonist with Ki of 58.4 nM, >100-fold selectivity over V1a, V2, V1b receptors.

WAY-362692 is a small molecule inhibitor of the secreted frizzled-related protein sFRP-1 with IC50 of 20 nM in FP binding assay.

WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).

WDR5 WIN site inhibitor C3 is a potent, specific WIN (WDR5 interaction) site inhibitor of WDR5 with Kd of 1.3 nM.

WDR5 WIN site inhibitor C6 is a potent, specific WIN (WDR5 interaction) site inhibitor of WDR5 with Kd of 0.1 nM.

WDR5-MLL1 inhibitor is a novel potent inhibitor of WDR5-MLL1 interaction, binds to WDR5 with Kd of 1 nM..

WEE1Hu inhibitor is a novel potent inhibitor of WEE1Hu kinase (also known as Wee1A) with IC50 of 68 nM against recombined WEE1Hu in ELISA assays.

WF-210 is a PAC-1 derivative and potent activator of procaspases-3 with EC50 of 0.95 uM, displays more cytotoxic than PAC‐1 to human cancer cells, but less cytotoxic to normal cells.

WHI-P97 is a rationally designed potent inhibitor of JAK-3.

Withaferin A is a steroid lactone that displays anti-inflammatory, antitumor and antiangiogenic activity, potently inhibits NF-κB activation by preventing the TNF-induced activation of IKKβ via a thioalkylation-sensitive redox mechanism.

WJ460 is one of the lead compounds exerting anti-metastatic activity in the nanomolar range in breast cancer cells.

Wnt signaling proteins are small secreted proteins that are active in embryonic development, tissue homeostasis, and tumorigenesis.1,2,3Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription. IWP-2 (Item No. 13951) is an inhibitor of Wnt production (IC50 = 27 nM) that inactivates porcupine, a membrane-bound O-acyltransferase whose palmitoylation activity is essential For the signaling ability and secretion of Wnt proteins.4 IWP-2-V2 is a less potent IWP-2 derivative whose chemical structure retains the benzothiazole group of its parent compound.4 It has been used to determine which structural features of IWP-2 are essential For impairing Wnt/β-catenin pathway activity.4For the detailed information of IWP-2-V2, the solubility of IWP-2-V2 in water, the solubility of IWP-2-V2 in DMSO, the solubility of IWP-2-V2 in PBS buffer, the animal experiment (test) of IWP-2-V2, the cell expriment (test) of IWP-2-V2, the in vivo, in vitro and clinical trial test of IWP-2-V2, the EC50, IC50,and Affinity of IWP-2-V2, Please contact DC Chemicals..

Wntepane 1 is a small-molecule activator of the Wnt pathway that modulates the van-Gogh-like receptor 1 (Vangl1), activates Wnt signaling with EC50 of 1.8 uM in the reporter gene assay.

Wnt-p53 inhibitor compound 2 is a novel inhibitor targets both Wnt signaling and ATM/p53, potently inhibits Wnt transcription (IC50=11 nM) and p53 transcription (EC50=1.9 nM).

WOBE-437 (WOBE437) is a potent, selective endocannabinoid uptake inhibitor with IC50 of 10 nM, with an outstanding 1,000-fold selectivity over FAAH.

WRG-28 (DDR2 inhibitor WRG-28) is a potent, selective, allosteric inhibitor of discoidin domain receptor 2 (DDR2) with binding IC50 of 230 nM.

WS-383 (WS383) is a highly potent, selective, and cellular active inhibitor of DCN1-UBC12 interaction with IC50 of 11 nM.

WS-383 hydrochloride (WS383) is a highly potent, selective, and cellular active inhibitor of DCN1-UBC12 interaction with IC50 of 11 nM.

WST-3 is a highly sensitive tetrazolium reagent (light red) which produces a water-soluble formazan (dark red color).

WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.

WWL113 is a potent inhibitor of Carboxylesterase Ces3 and Ces1f by competitive ABPP of enzymes recombinantly expressed in HEK293T cells (IC50 value of 0.1 uM for each enzyme).

WWL229 is a selective, distinct Carboxylesterase Ces3 inhibitor with IC50 of 1.94 uM, but not Ces1f, ABHD6, other serine hydrolases.

WX-037 (UCB-1370037) is a novel small molecule pan class I PI3K inhibitor with IC50 of 4.1, 2.4, 37 and 78 nM for PI3Kα, PI3Kδ, PI3Kγ and PI3Kβ, respectively.

WX-554 is an oral, small molecule allosteric inhibitor targeting mitogen-activated protein kinase kinase (MEK1 and MEK2) with an estimated IC50 of 4.7 and 10.7 nM, respectively.

WY-135 (WY135) is a novel potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively.

WYC-209 is a novel synthetic retinoid that inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with IC50 of 0.19 uM, targets retinoic acid receptor (RAR).

WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor

WYE-151650 is a novel potent, selective JAK3 inhibitor with IC50 of 0.8 nM, displays 36-, 14-, and 34-fold selectivity against JAK-1, JAK-2, and Tyk-2, respectively.

WYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2.1,2 It is a much weaker inhibitor of phosphatidylinositol 3-kinase α (IC50 = 1026 nM) and other kinases.3 WYE-354 i

WZ-4-49-8 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 67 nM.

Xamoterol (ICI 118587) is a third-generation adrenergic β1 adrenergic receptor partial agonist that acts as a cardiac stimulant..

Xamoterol (ICI 118587) is a third-generation adrenergic β1 adrenergic receptor partial agonist that acts as a cardiac stimulant..

Xanomeline(LY246708) is a selective M1 muscarinic receptor agonist.

Xanthotoxol is a coumarin and a major component in C. monnieri that has diverse biological activities.

Xanthyletin is a coumarin isolated from Citrus, with anti-tumor and anti-bacterial activities. Xanthyletin also inhibits symbiotic fungus cultivated by leaf-cutting ants.

XD14 is a BET bromodomain inhibitor with Kd values of 160, 170, 380, 490, 830 and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2) respectively.

XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.

XEN-402 (Funapide.

XF-73 (Exeporfinium chloride) is a novel broad-spectrum antibacterial agent that inhibits a range of gram-positive bacterial species (MIC=0.25-4 mg/mL), including Staphylococcus aureus.

XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM.

XL188 (XL-188) is a potent, selective, non-covalent active-site inhibitor of USP7 with IC50 of 90 nM and 193 nM for USP7 full length enzyme and catalytic domain, respectively.

XL-281 (BMS 908662) is a potent, selective, orally active inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models.

XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively.

XMD-17-51 is a potent NUAK1-specific NUAK1 inhibitor

XMU-MP-2 is a potent and selective BRK/PTK6 (breast tumor kinase) inhibitor with biochemical IC50 of 3.2 nM.

XR 5118 is a small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 3.5 uM, binds to PAI-1 and reduces plasma PAI-1 activity levels, promotes endogenous thrombolysis and inhibits thrombus accretion.

XR-5000 (Acridine Carboxamide.

XRK3F2 is an inhibitor of p62 (Sequestosome-1)-ZZ/ domain.

XX-650-23 is a small molecule inhibitor of CREB, blocks CREB/CBP interaction (IC50=3.2 uM) and disrupts CREB-driven gene expression.

XZH-5 is a small moelcule that inhibits constitutive and interleukin-6-induced STAT3 phosphorylation, inhibits STAT3 DNA binding ability and downregulation of STAT3 downstream genes.

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM. Antitumor activity.

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.

Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300.

Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

Y-39983 (Y39983) is a potent and selective p160 ROCK inhibitor with Ki of 140 nM.

YC-001 is a novel pharmacological chaperone of rod photoreceptor opsin, rescues the transport of multiple rod opsin mutants in mammalian cells.

YH12852 is a potent, highly selective 5-HT4 receptor agonist with pKi of 10.3, exhibits more potent agonistic activity (pEC50=11.4) than both tegaserod and prucalopride.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YIL-781 Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).

YK5 is a small molecule inhibitor of Hsp70 and Hsc70, induces the degradation of HER2, Raf-1, and Akt kinases, also induces apoptosis in the SKBr3 breast cancer cells..

YKL-1-116 is a potent, selective and covalent inhibitor of CDK7 that does not inhibit other CDKs.

YKL-5-124 is a novel potent, selective, and covalent CDK7 inhibitor (IC50=53.5 nM), inhibits CDK7/CycH/MAT1 enzymatic activity with IC50 of 9.7 nM.

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.

YM 254890 is a selective Gq signaling inhibitor that strongly inhibits intracellular calcium ion mobilization and serum response element (SRE)-mediated transcription stimulated by several receptors coupled to Gq, but not those coupled to Gi, Gs, or G15.

YM-1 is a close derivative of MTK-077 that allosterically promotes Hsp70 binding to unfolded substrates, specificly binds to Hsp70 with Kd of 4.9 uM.

YM116 is a potent CYP17A1 (17,20-lyase) inhibitor with IC50 with Ki of 0.38 nM, inhibits C17-20 lyase activity in human testicular microsomes with IC50 of 4.2 nM.

Yohimbine is an indole alkaloid that has high affinity for the α2-adrenergic receptors with Ki of 1 nM for α2A, α2B and α2C.

YPC-21661 is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143).

YPC-22026, a metabolically stable derivative of YPC-21661, is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143), inhibits the binding of ZNF143 to DNA.

YTX-465 (YTX465) is a specific small molecule that rescues yeast from a-Syn cytotoxicity with EC50 of 15 nM, via inhibiting Ole1, the yeast homolog of human stearoyl-CoA desaturase (SCD).

YU142670 is a highly specific, soluble OCRL/INPP5B inhibitor that directly interacts with the catalytic domain of INPP5B.

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor with inhibitory activity against PAD2 (IC50=0.5-1 uM) and PAD4 (IC50=1-2 uM), inhibits U2OS cancer cell growth with IC50 of 2.5 uM.

YZ129 (YZ-129) is a small molecule inhibitor of HSP90-Calcineurin-NFAT pathway, suppresses TG-induced NFAT nuclear translocation in HeLa cellswith IC50 of 820 nM.

Z433927330 (Z 433927330) is a potent and selective aquaporin-7 (AQP7) inhibitor, inhibits glycerol permeability in erythrocytes with IC50 of 0.6 uM..

Z-505 hydrochloride is a novel, orally active ghrelin (GHSR1a) agonist with EC50 of 2.08 nM and 5.46 nM for rat and mouse GHSR1a, respectively.

Z-590 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity.

Z62954982 is a potent, specific Rac1 inhibitor, reduces the intracellular levels of Rac1-GTP in a concentration-dependent manner with IC50 of 12 uM, 4 times more effective than NSC23766 (IC50=50 uM).

Z-944 is a potent, highly selective and oral T-type calcium channel blocker with IC50 of 50-160 nM for human Cav3.1, Cav3.2, and Cav3.3 channels.

Zaltoprofen(CN100) is an inhibitor of COX for treatment of arthritis.

Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.

Zanapezil (TAK-147) is a potent, selective acetylcholinesterase (AChE) inhibitor with IC50 of 97.7 nM.

Zaprinast (M&B 22948) is a potent, cGMP-specific phosphodiesterase inhibitor with IC50 of 0.5-0.76 and 0.15 uM for PDE5 and PDE6 respectively, also is an agonist for GPR35 (EC50=16/840 nM for rat/human GPR35).

Zatebradine hydrochloride is a bradycardic agent that creates use-dependent inhibition of hyperpolarization-activated current (If) in sinoatrial node cells (EC50 = 480 nM) and Purkinje fibres.

Zatebradine(UL-FS49) is a potent HCN channels antagonist, which decreased the heartbeat in a reversible manner; 92% inhibition of the hHCN1-mediated current at 10 uM.

Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast(CDP-323) is an oral α4-integrin inhibitor.

ZBMA-1 is a potent HIV-1 replication inhibitor (IC50=1.01 uM) that efficiently protects APOBEC3G protein by targeting Vif-APOBEC3G complex.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

ZD-7288 (ICI-D 7288) is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker.

ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP2) inhibitor being investigated for treatment of diabetes and obesity.

Zicronapine is an antipsychotic agent that shows potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors, exhibits monoaminergic activity and has a multi-receptorial profile..

Z-IETD-FMK is a specific Caspase-8 inhibitor.

Zifaxaban is a novel, potent, selective, direct and oral factor Xa inhibitor with IC50 of 11.1 nM (human FXa), displays > 10,000-fold selectivity than other serine proteases.

ZIKV inhibitor K22 is a small molecule that exerts a potent antiviral activity against a broad range of coronaviruses by targeting membrane-bound viral RNA replication, effectively inhibits ZIKV with IC50 of 2.1 uM

Z-Ile-Leu-aldehyde (Z-IL-CHO, GSI-XII, γ-Secretase inhibitor XII) is a potent gamma-secretase and Notch signaling inhibitor.

ZINC00881524 is a ROCK inhibitor.

ZINC02092166 is a novel potent, and selective small-molecule inhibitor for the β-catenin/Tcf4 protein-protein interaction with Ki of 1.7 and 7.0 uM in AlphaScreen and FP assay (wild-type β-catenin), respectively; remain affinity for muant catenin V511S, V511S/I569S and R469A with Ki of 20-50 uM; exhibits dual selectivity for β-catenin/Tcf over β-catenin/cadherin and β-catenin/APC PPIs.

ZINC12427628 (Compound '628) is a potent, selective positive allosteric modulator of M2 mAChR with EC50 of 1.1 uM.

ZINC-3573 racemate is a potent, selective agonist of the atypical opioid receptor MRGPRX2 (EC50=3 uM), showing little activity against 315 other GPCRs and 97 representative kinases.

ZINC549719643 (ZINC 549719643) is a potent, non-covalent AmpC inhibitor with IC50 of 77 nM. .

Zinterol (MJ 9184) is a potent and selective β2 adrenoceptor agonist with pKb of 8.3, displays >2 logs selectivity over β1 (pKb<5.7).

Zinterol (MJ 9184) is a potent and selective β2 adrenoceptor agonist with pKb of 8.3, displays >2 logs selectivity over β1 (pKb<5.7).

ZK 200775 is a competitive GluR (AMPA)/kainate antagonist.

ZK-216348 is a potent, selective, dissociated glucocorticoid receptor agonist with pIC50 of 7.7, shows selectivity over other nuclear hormone receptors..

ZK261991 is a highly selective and potent VEGFR-kinase inhibitor, which is orally available.

ZL-006 (ZL 006, ZL006) is a brain penetrant small molecule inhibitor of PSD-95/nNOS interaction that prevents glutamate-induced excitotoxicity and cerebral ischemic damage in vivo.

ZL0454 is a potent, highly selective small-molecule BRD4 inhibitor with IC50 of 49 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively.

ZLc002 (ZLc-002) is a putative small-molecule inhibitor of nNOS interaction with NOS1AP, disrupts neuronal nitric oxide synthase-NOS1AP interaction in intact cells.

ZLD1039 is an inhibitor of enhancer of zeste homolog 2 (EZH2; IC50 = 5.6 nM).

ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme ADAM-17, significantly decreases the level of NICD and accumulation of NICD in the nucleus; exhibits cytotoxic acitviity against MHCC97-H cells with IC50 of 5.32 uM, reduces the expression of pro-survival/anti-apoptosis regulators, Survivin and cIAP1/2, also increases the expression of epithelial marker E-Cadherin and reduces mesenchymal markers N-Cadherin and Vimentin in HCC cells; significantly disrupted the activity of Notch pathway in HCC cells and inhibits the epithelial-mesenchymal transition (EMT) process of HCC cells; ZLDI-8 treatment enhances the susceptibility of HCC cells to Sorafenib, Etoposide, and Paclitaxel both in vitro and in vivo.

Z-LEHD-FMK is a cell-permeable, competitive and irreversible inhibitor of enzyme caspase-9, which helps in cell survival.

ZLN024 Hcl is a novel AMPK allosteric activator; activated α1β1γ1 and α2β1γ1 by around 2–2.5 fold with an EC50 of about 1–2 uM. IC50 value: 1-2 uM (EC50) [1] Target: AMPK activator ZLN024 activated AMPK in L6 myotubes and stimulated glucose uptake and

ZM 323881 hydrochloride is a potent and selective inhibitor of human Flk-1 (vascular endothelial growth factor receptor 2, VEGFR-2/KDR) activity.

ZM323881 a receptor tyrosine kinase inhibitor of VEGFR-2 (Flk-1), PDGFR-beta, EGFR, and FGFR1

ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1, also potently inhibits human tissue transglutaminase (TGM2) with IC50 of 10 nM.

ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively.

Zofenopril Calcium(SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor.

Zonampanel (YM 872) is a selective, potent and highly water-soluble, competitive AMPA receptor (AMPAR) antagonist with Ki of 96 nM.

Zotarolimus (ABT-578, A 179578) is a semi-synthetic analogue of rapamycin, inhibits FKBP-12 binding with IC50 of 2.8 nM and shows less potent systemic immunosuppression than rapamycin.

ZPCK (NSC 251810.

ZST152 (ZST-152) is a small molecule DDAH1 (Dimethylarginine dimethylaminohydrolase 1) inhibitor.

ZST316 (ZST-316) is a small molecule DDAH1 (Dimethylarginine dimethylaminohydrolase 1) inhibitor with IC50 of 3 uM, Ki of 1 uM.

ZSTK474 is a potent pan-class I PI3K inhibitor with IC50 of 37 nM.

ZT-12-037-01 is a potent, selective, ATP-competitive STK19 inhibitor with IC50 of 20.04 nM measured as percentage of NRAS phosphorylation; shows similar IC50 of 23.96 and 27.94 nM for STK19WTWT STK19D89N respectively; displays extremely high kinase selectivity using KINOMEscan against a panel of 468 diverse kinases using an in vitro ATP-site competition binding assay at 1 uM; efficiently inhibits phosphorylation of NRAS in a dose- and time-dependent manner, inhibits NRAS activity in a dose-dependent manner but does not affect the levels of H3K9 methylation; effectively inhibits NRAS signaling, including the MEK-ERK and PI3K pathways in SK-MEL-2 and WM2032 cells (with NRASQ61R), but the inhibition was much less effective in A375 or UACC62 cells (with NRASWT), effectively inhibits cell growth and induces apoptosis of SK-MEL-2 and WM2032 melanoma cells.

ZT55 (JAK inhibitor ZT55) is a novel potent, highly-selective tyrosine kinase JAK2 inhibitor with IC50 of 31 nM.

ZTM000990 is a small-molecule antagonist of the oncogenic Tcf4/β-catenin protein complex with IC50 of 0.64 uM.

Z-VAD(OH)-FMK is an irreversible tripeptide inhibitor of all caspases.

Z-VDVAD-pNA is a colorimetric substrate for caspase-2.

ZXH-3-26 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), shows activity exclusively on the BRD4 BD1 (DC50/5h=5 nM) and spares degradation of BRD2 or BRD3 in cellular degradation assays.

ZYTP1 is a novel, oral PARP inhibitor that inhibits PARP1, PARP2, Tankyrase-1 and Tankyrase-2 with IC50 of 5.4, 0.7, 133.3 and 289.8 nM, respectively.

ZYZ-488 is a novel inhibitor of apoptotic protease activating factor-1 (Apaf-1), inhibits the activation of binding protein procaspase-9 and procaspase-3.

ZZW-115 (ZZW115, ZZW 115) is a potent inhibitor of NUPR1 (Kd=2.1 uM), an intrinsically disordered protein (IDP) with an entirely disordered conformation.

α2β1 integrin-IN-15 highly potent, selective, allosteric small-molecule inhibitor of integrin α2β1 with IC50 of 12 nM.

α5IA is a selective inverse agonist for Α5 subtype of GABAA receptor with a higher intrinsic activity at the A5 subtype than other drugs.

α-Amanitin, an 8-Aa cyclic peptide, is an selective inhibitor of RNA polymerase II and III.

α-Cyclodextrin is a multifunctional, soluble dietary fiber marketed for use as a fiber ingredient.

β-catenin-IN-11a is a β-catenin/CD44/Nanog axis inhibitor, docks into the β-catenin allosteric site and interferes β-catenin/TCF-4 complex.